title: Acrodermatitis continua of Hallopeau: evolution of treatment options.
abstract: Ever since its inception, acrodermatitis continua of Hallopeau, has been recognized as an uncommon clinical entity which has been sparingly reported from across the globe. The attempt to have cumulative information on prevalent nomenclature, definition, reminiscences, and clinical overtures has brought differential diagnosis and diagnosis in sharp focus, the highlights of which are outlined. Hence, it was considered important to review the evolution of treatment options available thus far including use of biologics.
authors.affiliation: Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Delhi, India. drsehgal@ndf.vsnl.net.in
authors.forename: Virendra N
authors.initials: VN
authors.lastname: Sehgal
authors.forename: Prashant
authors.initials: P
authors.lastname: Verma
authors.forename: Sonal
authors.initials: S
authors.lastname: Sharma
authors.forename: Govind
authors.initials: G
authors.lastname: Srivastava
authors.forename: Ashok K
authors.initials: AK
authors.lastname: Aggarwal
authors.forename: Farhan
authors.initials: F
authors.lastname: Rasool
authors.forename: Kingsuk
authors.initials: K
authors.lastname: Chatterjee
mesh_terms: D000169:Acrodermatitis / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D001688:Biological Products / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010789:Phototherapy; D011565:Psoriasis / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents